Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 13/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.39 |
| ▸ | GMNN | O75496 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | THPO | P40225 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18251683 | 0.89 | — | — | |
| SCHEMBL21991713 | 0.86 | CSNK2A1 (0.42) | CSNK2A1CSNK2A2CSNK2BMEN1RAB9A | |
| SCHEMBL17912754 | 0.77 | CSNK2A2 (0.48) | CSNK2A1CSNK2A2CSNK2BMEN1RAB9A | |
| SCHEMBL13928835 | 0.72 | CSNK2A1 (0.33) | CSNK2A1 | |
| SCHEMBL205514 | 0.72 | — | — | |
| SCHEMBL22939690 | 0.61 | — | — | |
| SCHEMBL27627272 | 0.60 | — | — | |
| SCHEMBL27285056 | 0.59 | DYRK1A (0.32) | DYRK1A | |
| SCHEMBL3675067 | 0.58 | NOD2 (0.38) | — | |
| SCHEMBL19848545 | 0.58 | CSNK2A2 (0.39) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1046 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104208-A1 | USE OF SUBSTITUTED HYDROQUINONES AS BROAD-SPECTRUM NITRIFICATION INHIBITOR (NI) | EUROCHEM ANTWERPEN (BE) | 2026-05-21 | — | — | WO | claimed |
| CN-115844883-B | Method for inhibiting porcine epidemic diarrhea virus in-vitro infection by tetrabromobenzotriazole and application thereof | 河南省农业科学院 | 2025-06-24 | — | — | CN | claimed |
| US-20250201928-A1 | LIQUID ELECTROLYTE FOR LITHIUM METAL BATTERIES | SYENSQO SA (BE) | 2025-06-19 | — | — | US | claimed |
| EP-4264709-B1 | ELECTROLYTE COMPOSITION FOR LITHIUM METAL BATTERIES | SYENSQO SA (BE) | 2025-03-19 | — | — | EP | claimed |
| CN-119462328-A | Preparation method of 1,3, 5-tribromobenzene intermediate of 1,3, 5-trimethoxybenzene | 江苏宝众宝达药业股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119335111-A | Mineral oil automatic detection method, equipment and medium based on secondary difference quotient filtration | 北京市科学技术研究院分析测试研究所(北京市理化分析测试中心) | 2025-01-21 | — | — | CN | claimed |
| CN-119213579-A | Electrolyte composition for lithium ion battery cells having anodes comprising a blend of silicon-carbon composite particles and graphite particles | 新罗纳米技术有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118843965-A | Liquid electrolyte for lithium metal battery | 西恩斯科公司 | 2024-10-25 | — | — | CN | claimed |
| US-12105231-B2 | Scintillator array for radiation detection | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-118712495-A | Power type lithium ion battery electrolyte, preparation method thereof and battery | 骆驼集团新能源电池襄阳有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2016022538-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TREATING CONDITIONS INVOLVING HSF1 ACTIVITY | DUKE UNIVERSITY (US) | 2016-02-11 | — | — | WO | claimed |
| US-20130210057-A1 | USE OF LABEL-FREE BIOSENSORS TO UNDERSTAND AND IDENTIFY TREATMENT FOR CANCER | CORNING INCORPORATED (US) | 2013-08-15 | — | — | US | claimed |
| US-20120022129-A1 | Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | claimed |
| WO-2010022043-A2 | TARGETING OF HISTONE DEACETYLASE 2 AND PROTEIN KINASE CK2 FOR TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF ROCHESTER MEDICAL CENTER (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048657-A1 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CLEVELAND STATE UNIVERSITY (US) | 2010-02-25 | — | — | US | claimed |
| WO-2009032213-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CLEVELAND STATE UNIVERSITY (US) | 2009-03-12 | — | — | WO | claimed |
| US-20090054507-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CLEVELAND STATE UNIVERSITY (US) | 2009-02-26 | — | — | US | claimed |
| WO-2008033308-A2 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CLEVELAND STATE UNIVERSITY (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2004058185-A2 | ANTIANGIOGENESIS BY INHIBITING PROTEIN KINASE CK2 ACTIVITY | CEDARS-SINAI MEDICAL CENTER (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040121968-A1 | Antiangiogenesis by inhibiting protein kinase CK2 activity | CEDARS-SINAI MEDICAL CENTER | 2004-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054507-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CSNK2A2, CSNK1G2, PACSIN2 | CSNK2A1 4/4885CSNK2A2 1/4885CSNK2B 6/4885 |
| US-20100048657-A1 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CSNK2A2, CSNK2A1, CSNK1G2 | CSNK2A1 2/4885CSNK2A2 1/4885CSNK2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.